Oova is proud to announce its Series A raise of $10.3 million, and introduce the new Oova Membership model, designed to provide unparalleled support and empowerment to women as they navigate fertility while trying to conceive. Unlike traditional one-time purchases or subscription-to-refill kits, the Oova Membership offers a comprehensive, ongoing solution for women's reproductive health.

This round is led by Spero Ventures, a firm committed to companies with a positive mission, who are creating new markets and solutions for their customers. Spero Ventures is joined by other strategic firms including US Fertility, Virgin Group, Jefferson Health, Connecticut Innovations, Special Situations Life Sciences Fund, Samsung Next, Hannah Bronfman, and Sara Blakely, the acclaimed businesswoman and founder of Spanx.

Oova is the fertility translator that fully illuminates a woman's fertility, giving her and her care team the clearest steps to conception. Founded by doctors and backed by Mount Sinai Hospital, Oova has created a consumer-first, data-driven experience valuable to patients and healthcare providers. Oova's at-home urine test measures luteinizing hormone and progesterone to immediately inform a woman of her most fertile days and confirm ovulation. By delivering advanced personalized analytics and real-time action plans with every hormone reading, Oova is transforming the fertility care experience. Oova has partnered with the leading fertility and women's health practices in the United States.